Mylan NV Chief Executive Officer Heather Bresch struggled to defend herself against harsh congressional questioning at a House Oversight Committee hearing Wednesday afternoon, after the company’s price hikes on the EpiPen allergic-reaction treatment sparked public backlash.

Lawmakers repeatedly referred to Mylan MYL, +0.27% “jacking” up the EpiPen’s price over the course of a combative two-hour hearing, asking Bresch to justify the price and rebuking her repeated assertions that the company collects only a small percentage of an over-$600 list price for an EpiPen two-pack.

Though Bresch sought to deflect questioning toward her company’s efforts to improve access to the EpiPen and a complicated pharmaceutical pricing ecosystem, lawmakers instead focused on the CEO herself: her executive compensation, which outpaces Mylan’s industry standing, and a recent USA Today report highlighting the role Bresch’s mother played as leader of a national education group while promoting EpiPen access in schools.

Read more:Things look even worse for Mylan CEO Heather Bresch as she heads to Capitol Hill

Lawmakers met Bresch’s discussion of Mylan’s work in schools to make the EpiPen more available with scorn.

“I was struck by what humanitarians you people of Mylan are,” said Rep. Gerry Connolly (D-Va.). “If you listened to your testimony, you’d never know what the uproar was about.”

In a rare showing of unity, lawmakers on both sides of the aisle strongly criticized Mylan’s actions. Several Republican representatives said that while they supported free-market capitalism, this was an example of the market failing to produce competitors and bring down the price of a lifesaving product.

Mylan CEO: EpiPen $608 Price Was 'Fair'

Bresch, clearly rattled through the course of the hearing, attempted to defend Mylan and herself.

The uproar, she said, “got ahead of the facts.”

“I know there is considerable concern and skepticism” about the price hikes, but net revenue for Mylan had increased at a much smaller rate, Bresch said. “Our profit is $100, or approximately $50 per pen.”

Read: Yes, you are paying a lot more for prescription drugs (and not just the EpiPen)

Bresch also claimed a USA Today article focusing on her mother’s role in facilitating EpiPens in schools was “completely inaccurate.”

“I certainly thought it was a very cheap shot to bring my mother into this,” Bresch said.

Remedies offered by Mylan in the weeks after a recent public backlash, which include a generic $300 EpiPen, an increased savings coupon value and expanded patient assistance programs, also came under attack.

See: Mylan’s EpiPen caught the full force of drug price outrage because it was the perfect target, not because it was the only one

“Why’d you lower it by half if you thought it was fair?” asked Rep. Scott DesJarlais (R-Tenn.). “If you thought it was fair, why not leave it where it’s at?... Lower the price so people can afford it.”

“The system wasn’t intended” for people to pay the entire list price of a drug, Bresch responded, referring to the rise of high-deductible health plans which increasingly shift costs to consumers, and which Mylan has said is a key factor in the recent EpiPen scandal.

Related: Mylan top executive pay was second-highest in industry just as company raised EpiPen prices

Bresch also said that the company will be making less profit on the generic than the branded EpiPen, despite only making it available through direct shipments to consumers, since “there are still fees, rebates and discounts on the generic channel, they’re just not as significant.”

The CEO also asserted that the EpiPen had competition throughout the course of the yearslong price hikes, though lawmakers pressed her on whether the product’s near-dominance in the market could be classified that way.

The Food and Drug Administration’s Dr. Douglas Throckmorton, deputy director for regulatory programs at the Center for Drug Evaluation and Research, was also present at the hearing, but was the subject of little questioning.

Lawmakers did ask Throckmorton about other epinephrine auto-injector products in the queue for FDA approval.

The official said four such products had been approved by the FDA, with two on the market, but said he could not comment on products pending approval.